טוען...
Development of rAAV2-CFTR: History of the First rAAV Vector Product to be Used in Humans
The first human gene therapy trials using recombinant adeno-associated virus (rAAV) vectors were performed in cystic fibrosis (CF) patients. Over 100 CF patients were enrolled in 5 separate trials of rAAV2-CFTR administration via nasal, endobronchial, maxillary sinus, and aerosol delivery. Recombina...
שמור ב:
| הוצא לאור ב: | Hum Gene Ther Methods |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Mary Ann Liebert, Inc.
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4834522/ https://ncbi.nlm.nih.gov/pubmed/26895204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/hgtb.2015.150 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|